Company Overview - Masimo is a global medical technology company known for its innovative monitoring technologies, including pulse oximetry, which is used on over 200 million patients annually [5] - The company went public in August 2007 at $17 per share and reached a high of $305.21 in November 2021, but experienced a decline of over 60% in the following months [6][9] Acquisition Details - Masimo has entered into a definitive agreement to be acquired by Danaher for $9.9 billion, with Danaher offering $180 in cash per share [1][8] - The acquisition has been unanimously approved by the boards of both companies and is expected to close in the second half of 2026, pending regulatory approvals [2] - Post-acquisition, Masimo will operate as a standalone business unit within Danaher's Diagnostics segment, enhancing Danaher's offerings in acute care settings [2][8] Financial Performance - Following the acquisition announcement, Masimo's shares surged nearly 35%, and over the past six months, the shares have risen 19.6%, contrasting with a 7% decline in the industry [3] - For Q4 2025, Masimo reported preliminary sales of $411 million, reflecting a 12% increase, with full-year revenues expected to be approximately $1.523 billion, indicating a 9% growth [14][15] Industry Prospects - The global pulse oximeter market was valued at approximately $3.34 billion in 2023 and is projected to grow at a CAGR of 6.9%, reaching about $5.33 billion by 2030, driven by increasing respiratory and cardiovascular diseases [12] - The demand for continuous monitoring devices, including pulse oximeters, is expected to rise due to technological advancements and the growing adoption of home healthcare [12][13]